Novel treatments in optic pathway gliomas

Akash Maheshwari; Mohammad Pakravan; Chaow Charoenkijkajorn; Shannon J. Beres; Andrew G. Lee

doi:10.3389/fopht.2022.992673

Novel treatments in optic pathway gliomas

Akash Maheshwari, Mohammad Pakravan, Chaow Charoenkijkajorn, Shannon J. Beres, Andrew G. Lee

Research output: Contribution to journal › Review article › peer-review

Abstract

Optic pathway gliomas (OPG) are primary tumors of the optic nerve, chiasm, and/or tract that can be associated with neurofibromatosis type 1 (NF1). OPG generally have a benign histopathology, but a variable clinical course. Observation is generally recommended at initial diagnosis if vision is stable or normal for age, however, treatment may include chemotherapy, radiotherapy, or surgery in select cases. This manuscript reviews the literature on OPG with an emphasis on recent developments in treatment.

Original language	English (US)
Article number	992673
Journal	Frontiers in Ophthalmology
Volume	2
DOIs	https://doi.org/10.3389/fopht.2022.992673
State	Published - 2022
Externally published	Yes

Keywords

BRAF inhibitor
MEK inhibitor
bevacizumab
chemotherapy
immunotherapy
low grade glioma
optic pathway glioma
stereotactic radiation

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.3389/fopht.2022.992673

Cite this

@article{4d1a773aaba947f18e4f8e5a29bf405c,

title = "Novel treatments in optic pathway gliomas",

abstract = "Optic pathway gliomas (OPG) are primary tumors of the optic nerve, chiasm, and/or tract that can be associated with neurofibromatosis type 1 (NF1). OPG generally have a benign histopathology, but a variable clinical course. Observation is generally recommended at initial diagnosis if vision is stable or normal for age, however, treatment may include chemotherapy, radiotherapy, or surgery in select cases. This manuscript reviews the literature on OPG with an emphasis on recent developments in treatment.",

keywords = "BRAF inhibitor, MEK inhibitor, bevacizumab, chemotherapy, immunotherapy, low grade glioma, optic pathway glioma, stereotactic radiation",

author = "Akash Maheshwari and Mohammad Pakravan and Chaow Charoenkijkajorn and Beres, {Shannon J.} and Lee, {Andrew G.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Maheshwari, Pakravan, Charoenkijkajorn, Beres and Lee.",

year = "2022",

doi = "10.3389/fopht.2022.992673",

language = "English (US)",

volume = "2",

journal = "Frontiers in Ophthalmology",

issn = "2674-0826",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Novel treatments in optic pathway gliomas

AU - Maheshwari, Akash

AU - Pakravan, Mohammad

AU - Charoenkijkajorn, Chaow

AU - Beres, Shannon J.

AU - Lee, Andrew G.

PY - 2022

Y1 - 2022

N2 - Optic pathway gliomas (OPG) are primary tumors of the optic nerve, chiasm, and/or tract that can be associated with neurofibromatosis type 1 (NF1). OPG generally have a benign histopathology, but a variable clinical course. Observation is generally recommended at initial diagnosis if vision is stable or normal for age, however, treatment may include chemotherapy, radiotherapy, or surgery in select cases. This manuscript reviews the literature on OPG with an emphasis on recent developments in treatment.

AB - Optic pathway gliomas (OPG) are primary tumors of the optic nerve, chiasm, and/or tract that can be associated with neurofibromatosis type 1 (NF1). OPG generally have a benign histopathology, but a variable clinical course. Observation is generally recommended at initial diagnosis if vision is stable or normal for age, however, treatment may include chemotherapy, radiotherapy, or surgery in select cases. This manuscript reviews the literature on OPG with an emphasis on recent developments in treatment.

KW - BRAF inhibitor

KW - MEK inhibitor

KW - bevacizumab

KW - chemotherapy

KW - immunotherapy

KW - low grade glioma

KW - optic pathway glioma

KW - stereotactic radiation

UR - http://www.scopus.com/inward/record.url?scp=85183652564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85183652564&partnerID=8YFLogxK

U2 - 10.3389/fopht.2022.992673

DO - 10.3389/fopht.2022.992673

M3 - Review article

AN - SCOPUS:85183652564

SN - 2674-0826

VL - 2

JO - Frontiers in Ophthalmology

JF - Frontiers in Ophthalmology

M1 - 992673

ER -

Novel treatments in optic pathway gliomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this